DUBLIN, October 13, 2017 /PRNewswire/ --
The "Global Label-free Detection (LFD) Market 2017-2021" report has been added to Research and Markets' offering.
The global label-free detection (LFD) market to grow at a CAGR of 10.76% during the period 2017-2021.
Global Label-free Detection (LFD) Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.
One trend in the market is potential opportunities for POL. Across the globe, there is neither uniformity nor support for the use of decentralized IVD tests in primary healthcare and outpatient settings. These tests are often performed in POL. The payers, regulators, and administrators are required to address the importance of POL testing as there are technical advances in portable IVD instruments.
According to the report, one driver in the market is rise in drug discovery programs. The increasing incidence of chronic diseases such as respiratory diseases, chronic kidney diseases, leukemia, and others have contributed to the rise in drug discovery. Various drug discovery programs organized by many academic and research institutes across the world. The drug development helps in testing the toxicity of drug and efficacy at the target tissue or organ in a patient. Rise in drug discovery results in an increased demand for personalized medicines in the market. The market also witnesses an increase in partnership between academic research institutes and major pharmaceutical/ biotechnology companies.
Further, the report states that one challenge in the market is strained laboratory budgets and decline in reimbursement. The reimbursement policies for diagnostic testing are not constant across different geographies and they are moving in downward trend. The hospitals and diagnostic laboratories that are the primary end-user group are forced to reduce their expenditure on in-vitro diagnostic (IVD) instruments to have either break even or profitable revenue.
- Bio-Rad Laboratories
- GE Healthcare
- F.Hoffman-La Roche
Other prominent vendors
- Juno Therapeutics
Key Topics Covered:
Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Market Landscape
Part 06: Market Segmentation By Product
Part 07: Market Segmentation By End-User
Part 08: Geographical Segmentation
Part 09: Decision Framework
Part 10: Drivers And Challenges
Part 11: Market Trends
Part 12: Vendor Landscape
Part 13: Key Vendor Analysis
Part 14: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/3xdllw/global_labelfree
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets